- XPhyto Therapeutics Corp. is a life sciences technology accelerator involved in the development of new pharmaceuticals, diagnostic products and psychedelic investments
- XPhyto is preparing a series of clinical pilot studies for four drug candidates this year that could help in treating Parkinson’s disease, epilepsy, anorexia and other neurological conditions
- The company has developed a rapid and highly portable PCR test kit it expects to commercialize this year to provide point-of-care diagnostics, designed for satellite labs to quickly screen for the COVID-19 virus
- Wholly owned subsidiary Vektor, a German drug maker and researcher, plans to build a new commercial drug manufacturing facility this year to help advance XPhyto’s vertical integration plans
Bioscience industry holding company XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is accelerating its mission to advance next-generation drug delivery, diagnostic products and new active pharmaceutical ingredient investment opportunities following a series of successes in 2020 that kept the company productive despite global pandemic conditions.
The goals for the coming year include wholly owned subsidiary Vektor’s construction of a new commercial drug manufacturing facility in Germany, clinical pilot studies for four drug formulation programs XPhyto built up during 2020, taking its COVID-19 PCR test and at least one of its novel, in-house-manufactured biosensor products to market, and the&
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://cnw.fm/XPHYF
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.